Published

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Molecular psychiatry
Date: 2023-09-01
Source: PubMed
DOI: 10.1038/s41380-023-02280-z
PubMed: 37783788

Authors

Kiilerich KF Lorenz J Scharff MB Speth N Brandt TG Czurylo J Xiong M Jessen NS Casado-Sainz A Shalgunov V Kjaerby C Satała G Bojarski AJ Jensen AA Herth MM Cumming P Overgaard A Palner M

Watch author

Derived topics and classifications

psilocybin Anxiety Neuroplasticity Receptor Pharmacology Microdosing Resilience Animal Study Animal Study

Citation graph

0 referenced DOIs found in stored source metadata. 7 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats2026-10-01 Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortex2026-07-28 Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review2026-07-01 Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats2026-07-01 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15 Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure2026-02-12 Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.2023-09-01

Related papers

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-25 An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17 Processing Intergenerational Trauma With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-08-13 TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-08-12